Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
79.74 USD | +0.62% | +0.33% | -3.20% |
Apr. 26 | Medtronic Receives FDA Approval for Inceptiv Spinal Cord Stimulator to Treat Chronic Pain | MT |
Apr. 26 | Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 22.77 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.98 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.20% | 106B | C | ||
-2.31% | 187B | C+ | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.07% | 26.48B | B | ||
+2.36% | 26.25B | A- | ||
+12.96% | 24.62B | A- | ||
-1.93% | 24.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MDT Stock
- Ratings Medtronic plc